Abbott Laboratories’s (NYSE:ABT) Q3 2026 earnings results: revenue in line with expectations

Healthcare product and device company Abbott Laboratories (NYSE:ABT) met Wall Street’s revenue expectations in Q3 2026, with sales up 14.5% year on year to $13.01 billion. Its non-GAAP profit of $1.42 per share was in line with analysts’ consensus estimates.